Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b open-label maintenance study of obefazimod in moderate to severe ulcerative colitis
2019-000733-39Phase 2Completed
- Sponsor
- Abivax
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obefazimod in autoimmune colitis, sponsored by Abivax. Primary endpoint: Clinical remission at week 48. Started Sep 2019; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-000733-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000733-39.